45th week of 2008 patent applcation highlights part 39 |
Patent application number | Title | Published |
20080275027 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists - The invention relates to compounds of formula (I) or salts and solvates thereof, processes for their preparation, to compositions containing them and to their use in the treatment of various disorders, such as allergic rhinitis: | 2008-11-06 |
20080275028 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof - The present invention relates to compounds with α7 nAChR agonistic activity, processes for their preparation, pharmaceutical compositions containing the same and the use thereof for the treatment of neurological, psychiatric, cognitive, immunological and inflammatory disorders. | 2008-11-06 |
20080275029 | Compounds for Treating Protein-Kinase Mediated Disorders - The invention provides a compound of the formula (I) or a salt, solvate, tautomer or N-oxide thereof for use in the treatment or prophylaxis of a disease state or condition mediated by protein kinase A and/or protein kinase B; | 2008-11-06 |
20080275030 | Methods and Compositions for the Delivery of a Therapeutic Agent - The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal. | 2008-11-06 |
20080275031 | Inhibitors of C-FMS Kinase - The invention is directed to compounds of Formula I: | 2008-11-06 |
20080275032 | Pyridazinone compounds - The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus. | 2008-11-06 |
20080275033 | BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES - A phenothiazinium compound of Formula (I) | 2008-11-06 |
20080275034 | Use of a Phenothiazine Derivative for Preventing and/or Treating Hearing Loss - The invention concerns the use of a phenothiazine derivative of formula (I), wherein: R represents the hydrogen atom, an alkyl radical, arylalkyl, or —C(O)R′, for preparing a medicine for preventing and/or treating hearing loss. | 2008-11-06 |
20080275035 | Nitroimidazole Compounds - The present invention relates to certain nitroimidazole compounds, which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and/or prevention of infections such as those caused by | 2008-11-06 |
20080275036 | Prevention and treatment of cardiac conditions - The present invention provides a method of treating conditions associated with iron and calcium overload comprising administering an effective amount of dexrazoxane or a non-dexrazoxane compound of formula (IA), (IB), or (IC) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. | 2008-11-06 |
20080275037 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof - Fused heterocyclic compounds are provided according to formula 1: | 2008-11-06 |
20080275038 | Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists - The present disclosure relates to imidazopyridine derivatives of formula (I): | 2008-11-06 |
20080275039 | Geldanamycin Derivatives and the Method for Biosynthesis Thereof - The present invention relates to geldanamycin derivatives, benzoquinone ansamycin biosynthesized by gene manipulation of | 2008-11-06 |
20080275040 | 8-(1-Piperazinyl)-Quinoline Derivatives and Their Use in the Treatment of Cns Disorders - This invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders. | 2008-11-06 |
20080275041 | 3-Heterocyclyl-Indole Derivatives as Inhibitors of Glycogen Synthase Kinase-3 (Gsk-3) - Compounds of formula Ia or Ib | 2008-11-06 |
20080275042 | 4-Phenyl-5-Oxo-1,4,5,6,7,8-Hexahydroquinoline Derivatives for the Treatment of Infertility - The present invention relates to 4-phenyl-5-oxo-1,4)5,6,7,8-hexahydroquinoline derivatives according to Formula I, Formula I or a pharmaceutically acceptable salt thereof, wherein R | 2008-11-06 |
20080275043 | Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 - The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Fomula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia. | 2008-11-06 |
20080275044 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them and use thereof for treating pain and other conditions - Compounds corresponding to formula I: | 2008-11-06 |
20080275045 | Potassium Channel Modulating Agents and Their Medical Use - This invention relates to novel potassium channel modulating agents, and their use in the preparation of pharmaceutical compositions. | 2008-11-06 |
20080275046 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses - The present invention relates to compounds comprising an oxazole or thiazole moiety of formula (I), processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H | 2008-11-06 |
20080275047 | TETRAHYDRO-NAPHTHALENE DERIVATIVES - This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as an active ingredient of pharmaceutical preparations. The tethrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontienence, chronic pain, neuropathic pain, post-operative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD. | 2008-11-06 |
20080275048 | Substituted Diazabicycloalkane Derivates - Compounds of formula (I) | 2008-11-06 |
20080275049 | Methods and Compositions for Upregulation of GATA Activity - A novel method of identifying compounds capable of upregulating GATA activity is disclosed. The method includes providing a sample of cells that express GATA, providing a sample of a candidate compound, contacting the cell sample and the compound sample, and measuring a quantitative indicator of GATA activity within the cell sample after the contacting step. GATA inducers identified by the method and uses therefore to upregulate GATA activity in subjects and to prevent or treat atherosclerosis or diabetes in subjects are also described. | 2008-11-06 |
20080275050 | Pyridazine Compound and Use Thereof - A pyridazine compound represented by the formula (1): | 2008-11-06 |
20080275051 | Preparation of High Purity Substituted Quinoxalines - The present invention comprises an improved process for the preparation of substituted quinoxaline I by cyclization of the corresponding dianiline. | 2008-11-06 |
20080275052 | HETEROBICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS - A compound of Formula (I) | 2008-11-06 |
20080275053 | Heterocyclyl Compounds - Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: | 2008-11-06 |
20080275054 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors - The invention relates to novel pyrazolo[3,4-d]pyrimidines of the formula | 2008-11-06 |
20080275055 | IMATINIB PRODUCTION PROCESS - Provided is a process for producing imatinib and salts thereof, e.g., imatinib mesylate. The process includes reacting4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid with N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine in the presence of a carboxylic acid coupling reagent, to produce imatinib, and optionally converting the imatinib into a salt. | 2008-11-06 |
20080275056 | Pyrazole-Isoquinoline Urea Derivatives as P38 Kinase Inhibitors - The present invention provides kinase inhibitors of Formula (I) wherein R1, R2, and X are as described herein, or a pharmaceutically acceptable salt thereof. | 2008-11-06 |
20080275057 | Compounds with anti-cancer activity - Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents. | 2008-11-06 |
20080275058 | N-Substituted-1H-Quinoline-2,4-Diones, Preparation Method Thereof, And Pharmaceutical Composition Containing The Same - The present invention relates to compounds of N-substituted -1H-quinoline-2,4-diones acting as a 5HT6 receptor antagonist, a preparation method thereof, and a pharmaceutical composition containing the same for treatment of the central nervous system disorders. The compounds of N-substituted-1H-quinoline-2,4-diones according to the present invention have excellent binding affinity for the 5HT6 receptor and excellent selectivity for the 5HT6 receptor over other receptors. Also, the compounds reverse a disruption of PPI by methamphetamine and don't show rotatod deficit in mice. Thereof the compounds according to the present invention may be valuably used for treatment if a 5HT6 receptor relating disorder | 2008-11-06 |
20080275059 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES - The present invention relates to a compound represented by the formula (I): | 2008-11-06 |
20080275060 | N-Hydroxyamide Derivatives and Use Thereof - The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis. | 2008-11-06 |
20080275061 | METHOD FOR CONTROLLING PARTICULAR INSECT PESTS BY APPLYING ANTHRANILAMIDE COMPOUNDS - This invention pertains to a method for controlling lepidopteran, homopteran, hemipteran, thysanopteran and coleopteran insect pests comprising contacting the insects or their environment with an arthropodicidally effective amount of a compound of Formula I, its N-oxide or an agriculturally suitable salt thereof | 2008-11-06 |
20080275062 | Chemical Compounds - There is provided compounds of Formula (I) and salts, solvates, and physiologically functional derivatives thereof: | 2008-11-06 |
20080275063 | Inhibitors of protein kinases - The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceutical compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases. | 2008-11-06 |
20080275064 | Substituted Pyrimidines as Adenosine Receptor Antagonists - Compounds of formula (I), including pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof, R | 2008-11-06 |
20080275065 | Novel Insecticides - Compounds of formula I | 2008-11-06 |
20080275066 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists - The invention provides compounds of formula (I) for use as GLP-1 receptor agonists. | 2008-11-06 |
20080275067 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta - Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed. | 2008-11-06 |
20080275068 | Method of Using Vasoconstrictive Agents During Energy-Based Tissue Therapy - A mammal undergoing an energy-based therapy is treated by administering at least one vasoconstrictive agent to the mammal prior to or during the procedure. The at least one vasoconstrictive agent is added in amounts sufficient to reduce or prevent vasodilation. This treatment method increases or promotes the size of the coagulation zone created after energy-based therapy. | 2008-11-06 |
20080275069 | Quinazoline Derivative - This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) | 2008-11-06 |
20080275070 | Aryl Ether Compounds and Their Preparation and Use Thereof - The invention relates to aryl ether compounds and its preparation method and use thereof. The aryl ether compounds of the invention having general formula (I): | 2008-11-06 |
20080275071 | Radiotherapy Enhancer - The present invention relates to a radiotherapy enhancer that can reduce the radiation dose and adverse drug reactions when used in combination with a cancer radiotherapy. A radiotherapy enhancer comprising (A) tegafur and (B) gimeracil. | 2008-11-06 |
20080275072 | WEEKLY ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS - Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions. | 2008-11-06 |
20080275073 | CRYSTALLINE FORMS AND POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS PHARMACEUTICALLY ACCEPTABLE SALTS - The present invention relates to one or more crystalline forms and polymorphs of compounds of formula I: | 2008-11-06 |
20080275074 | Anti-Itching Agent - A novel antipruritic useful for the treatment of pruritus accompanying various diseases is disclosed. The antipruritic comprises a specific morphinan derivative having a nitrogen-containing cyclic group or the pharmaceutically acceptable acid addition salt thereof such as N-(17-cyclopropylmethyl-4,5α-epoxy-3,14-dihydroxy-morphinan-6β-yl)-phthalimide hydrochloric acid salt | 2008-11-06 |
20080275075 | Medicine Comprising a Combination of an Acetylcholinesterase Inhibitor and a 5-Substituted-3-Oxadiazolyl-1,6-Naphthyridin-2(1H)-One Derivative - The invention provides a medicine comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1H)-one derivative of the formula (I): | 2008-11-06 |
20080275076 | Pharmaceutical Compositions Comprising Sirolimus and/or an Analogue Thereof - The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising sirolimus (rapamycin) and/or derivatives and/or analogues thereof. Compositions of the invention exhibit an acceptable bioavailability of sirolimus and/or a derivative and/or an analogue thereof. The pharmaceutical compositions of the invention are designed to release sirolimus in a controlled manner so that the plasma levels stays within the narrow therapeutic window that exist for this class of substances. An extended release profile, where the peak concentration has been reduced without loosing significant bioavailability, together with less variable absorption, is expected to improve the safety/efficacy ratio of the drug. Furthermore, compositions according to the invention provide for a significant reduced food effect and a delayed release of sirolimus is expected to reduce the number of gastro-intestinal related side effects. | 2008-11-06 |
20080275077 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER - Pharmaceutical formulations comprising an immune response modifier (IRM) chosen from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazolo-quinolineamines, oxazolo-quinolinamines, thiazolo-pyridinamines, oxazolo-pyridinamines, imidazonaphthyridine amines, tetrahydroimidazonaphthyridine amines, and thiazolonaphthyridine amines; a fatty acid; and a hydrophobic, aprotic component miscible with the fatty acid are useful for the treatment of dermal associated conditions. Novel topical formulations are provided. In one embodiment, the topical formulations are advantageous for treatment of actinic keratosis, postsurgical scars, basal cell carcinoma, atopic dermatitis, and warts. | 2008-11-06 |
20080275078 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors - The invention provides a compound of formula (I) or a salt thereof: | 2008-11-06 |
20080275079 | M3 Muscarinic Acetylcholine Receptor Antagonists - Muscarinic Acetylcholine receptor antagonists and methods of using them are provided. | 2008-11-06 |
20080275081 | Novel thrombomodulin expression promoters - It is intended to provide a novel pharmaceutical effect of HMG-COA reductase inhibitors, in particular, (+)-(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-di hydroxy-6-heptenoic acid or its salt. Namely, TM expression promoters, more specifically speaking, antithrombotic drugs, preventive/remedies for sepsis, antiplatelet drugs and anticoagulants comprising as the active ingredient an HMG-COA reductase inhibitor, in particular, (+)-(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid or its salt. | 2008-11-06 |
20080275082 | Pharmaceutical Composition - A novel pharmaceutical composition comprising the NK | 2008-11-06 |
20080275083 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLES - The present invention relates to 2,3,4,9-tetrahydro-1H-carbazoles of the general formula I, | 2008-11-06 |
20080275084 | Piperidines for the Treatment of Chemokine Mediated Diseases - The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state. | 2008-11-06 |
20080275085 | Piperidine derivative and use thereof - The present invention provides a novel piperidine derivative and a tachykinin receptor antagonist containing same, as well as a compound represented by the formula: | 2008-11-06 |
20080275086 | Dpp-Iv Inhibitors - The invention relates to compounds of formula (I) | 2008-11-06 |
20080275087 | BIPHENYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS - Biphenylcarboxamide compounds of formula (I) | 2008-11-06 |
20080275088 | Use of Collismycin and Derivatives Thereof as Oxidative Stress Inhibitors - The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease. | 2008-11-06 |
20080275089 | Compositions and methods to treat gastrointestinal disorders - The invention provides safe and effective methods for treating and preventing dysphagia, lower esophageal mucosal rings, esophageal strictures, achalasia, gastric mucosal injuries, and bacterial infections. The methods comprise administering at least one proton pump inhibitor, optionally in combination with antibacterial compounds. In one embodiment, the proton pump inhibitor is rabeprazole, a pharmaceutically acceptable salt thereof and/or a stereoisomer thereof. | 2008-11-06 |
20080275090 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS - The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y | 2008-11-06 |
20080275091 | COMPOSITIONS AND METHODS FOR TREATING NOCTURNAL ACID BREAKTHROUGH AND OTHER RELATED DISORDERS - The present invention relates to, inter alia, pharmaceutical compositions comprising an acid labile proton pump inhibitor and a buffering agent; to methods for manufacture of such compositions, and to use of such compositions in treating and preventing diseases and/or disorders. | 2008-11-06 |
20080275092 | ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS - The present invention relates to compounds having the formula, | 2008-11-06 |
20080275093 | Diuretic Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use - The invention describes novel diuretic compounds comprising at least one heterocyclic nitric oxide donor group, or pharmaceutically acceptable salts thereof, and novel composition comprising at least one diuretic compound comprising at least one heterocyclic nitric oxide donor group, and optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one diuretic compound of the invention comprising at least one heterocyclic nitric oxide donor group, and optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidatives stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; and (p) treating sexual dysfunctions. The heterocyclic nitric oxide donors are preferably furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines. | 2008-11-06 |
20080275094 | 5-(1,3-Diaryl-1H-Pyrazol-4-1 Methylene)-Thiazolidine-2,4-Dione Derivatives Useful as Anticancer Agent - The present invention relates to a 5-(1,3-diaryl-1H-pyrazol-4-ylmethylene)-thiazolidine-2,4-dione derivative or its pharmaceutically acceptable salts thereof, a method for preparing the same and an anticancer agent composition comprising the same as an active ingredient. | 2008-11-06 |
20080275095 | Combination of Prostaglandin E2 Receptor Antagonists and Renin-Angiotensin System Inhibitors for Treating Renal Diseases - This invention relates to methods for treating renal diseases by using combination of prostaglandin E2 receptor antagonist and renin-angiotensin system inhibitor and pharmaceutical compositions for treating renal diseases comprising prostaglandin E2 receptor antagonist and renin-angiotensin system inhibitor. | 2008-11-06 |
20080275096 | Process for the preparation of valsartan - Provided is a process for preparing valsartan and precursors thereof. | 2008-11-06 |
20080275097 | Non-nucleoside reverse transcriptase inhibitors - Compounds of Formula I: | 2008-11-06 |
20080275098 | NOVEL SUBSTITUTED 2-AMINOIMIDAZOLES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENT OR DIAGNOSTIC AID - The present invention comprises novel substituted 2-aminoimidazoles of formula I, processes for their preparation, pharmaceutical compositions thereof, and methods for their use in the treatment of disorders of the central nervous system, cardiovascular disorders, stroke and pulmonary disorders, urinary disorders such as acute or chronic renal failure, disorders of biliary function, respiratory disorders such as snoring or sleep apnea. | 2008-11-06 |
20080275099 | Solid Forms of (E)-1-(4-((1R,2S,3R)-1,2,3,4-Tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone Oxime - Solid forms of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime, compositions comprising them, and methods of their use are disclosed. | 2008-11-06 |
20080275100 | PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE - The invention provides para substituted dialkylphenol derivatives of propofol. The invention further provides pharmaceutical compositions comprising such analogs, methods for preparing such analogs, and methods of using such analogs to induce general anesthesia, sedation, and/or hypnotic or sleep effects in a patient. | 2008-11-06 |
20080275101 | Solid Salt Forms Of A Pyrrole Substituted 2-Indolinone - The present invention relates to solid salt forms of the 3-pyrrole substituted 2-indolinone compound 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide. It also relates to polymorphs of the phosphate salt of the amide. The invention further relates to the use of the salts and polymorphs in the treatment of protein kinase related disorders. | 2008-11-06 |
20080275102 | 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF - The invention relates to compounds of formula (I), wherein X, R | 2008-11-06 |
20080275103 | Anti-Tubulin Acting Arylpyrrol, Arylfuran And Arylthiophene Derivatives, Method For The Preparation Thereof And For The Use Thereof As An Antimitotic - The invention relates to a compound represented by general formula (I) wherein Z represents N, O or S, and A represents a CH group, a nitrogen atom or an NL | 2008-11-06 |
20080275104 | METHODS OF TREATING JUVENILE TYPE 1 DIABETES MELLITUS - The present disclosure describes methods for treating Type 1 diabetes mellitus in juveniles. This treatment of Type 1 diabetes is achieved by administering one or more therapeutic agents to a juvenile in need, wherein the therapeutic agent is, for example, a competitive inhibitor of mevalonate synthesis, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, or an inducer of AMP protein kinase (AMPK) activity. In certain embodiments, juveniles with Type 1 diabetes are treated with an HMG-CoA reductase inhibitor such as a statin. | 2008-11-06 |
20080275105 | Selective Muscle Relaxant and Pharmaceutical Compositions - This invention refers to substances able to cause selective muscle relaxation, pharmaceutical compositions containing such compounds and their use in the treatment of muscle tissue diseases, with such compounds complying with the general formula (I). | 2008-11-06 |
20080275106 | Anticancer and Antiprotozoal Dihydroartemisinene and Dihydroartemisitene Dimers with Desirable Chemical Functionalities - This invention comprises compositions containing dihydroartemisinin- and dihydroartemisitene-dimers with activity as anticancer or anticancer metastasis agents and anti-protozal, including anti-malarial and anti-leishmanial properties. This invention also describes methods of preparation of these compositions and methods of use of such compositions for the treatment of cancer or prevention of cancer metastasis, and protozoal infections, including malaria, or leishmaniasis. The compounds of this invention represent a potential new class of anti-tumor or anti-metastasis agents, one that has shown promising activity against solid tumors. | 2008-11-06 |
20080275107 | TOPICAL FORMULATIONS AND METHODS FOR ELIMINATION AND PROPHYLAXIS OF SUSCEPTIBLE AND TREATMENT RESISTANT STRAINS OF HEAD LICE WITH MULTIPLE MODES OF ACTION - Topical formulations for prophylaxis or elimination of susceptible and treatment resistant head lice wherein the formulation is an aqueous dispersion of an oil phase containing an effective amount of an active ingredient component combining at least one compound that binds to glutamate-gated chloride ion channels and at least one compound that binds to gamma-amino butyric acid (GABA) receptors, dissolved in at least one water-soluble or water-miscible surface active agent with one or more suspending agents and one or more non-ionic surfactants. Also disclosed are methods of using the topical formulations to treat or prevent an infestation of either a susceptible or treatment resistant strain of head lice in a human patient. | 2008-11-06 |
20080275108 | VACUOLAR-TYPE (H+)-ATPase-INHIBITING COMPOUNDS, COMPOSITIONS, AND USES THEREOF - The present invention provides vacuolar-type (H+)-ATPase-inhibiting compounds, compositions thereof, and methods of using them to treat or prevent a condition treatable by the inhibition of a vacuolar-type (H+)-ATPase. The composition of the present invention comprises a compound of the present invention and a carrier. The method of the present invention includes administering a vacuolar-type (H+)-ATPase inhibiting-effective amount of a compound of the present invention. The compound of the present invention has the formula: | 2008-11-06 |
20080275109 | NEUTRALIZING AGENT FOR VACUOLATING TOXIN - A drug, quasi drug, food or drink product containing a proanthocyanidine derived from hop, hop bract or apple has the effect of neutralizing or attenuating a vacuolacting toxin produced by | 2008-11-06 |
20080275110 | Sesamin/Episesamin Compositions - Sesamin and episesamin are incorporated at specified weight ratios in oral compositions so that the oral absorption of episesamin and/or its transfer into blood circulation is increased. Sesamin and episesamin are also incorporated at specified weight ratios in oral compositions so that the physiological activities of sesamins are enhanced. | 2008-11-06 |
20080275111 | Novel Use of Lignan Compounds - The present invention relates to the novel use of lignan compounds represented by Formula I. More particularly, the present invention relates to a pharmaceutical composition for treating or preventing a brain disease, comprising a lignan compound represented by Formula I or a | 2008-11-06 |
20080275112 | Invention Concerning Aminoadamantane Compounds - The present invention describes 1-aminoadamantane derivatives and 3-aminoadamantane-1-carboxylic derivatives in which the 5- or 7-position of the basic adamantane structure can be optionally substituted, methods for the production of the compounds based on the present invention, and methods for the coupling of the monomeric 3-aminoadamantane-1-carboxylic derivatives thus obtained to oligomers. The compounds based on the present invention are suitable for the utilisation as antiviral active ingredients, artificial ion channels, as well as for the therapy, diagnostics and prophylaxis of diseases in which a dysfunction of the GABA system occurs. | 2008-11-06 |
20080275113 | Antimicrobial Compositions, Products, And Methods Of Use - The present invention comprises an antimicrobial composition. More particularly to an antimicrobial composition that comprises a. from about 0.01% to about 15% of at least one non-anionic surfactant, by weight of the composition; b. from about 0.01% to about 15% of at least one acid, by weight of the composition; c. from about 0% to about 99.85% of water, by weight of the composition; and wherein the composition is foaming. | 2008-11-06 |
20080275114 | Inhibitors of Ccr9 Activity - Compounds of formula (I), in which R | 2008-11-06 |
20080275115 | Insecticidal Compositions Suitable for Use in Preparation of Insecticidal Granular Fertilizer and Insecticidal Formulations - Insecticidal compositions suitable for use in preparation of insecticidal granular fertilizer and insecticidal formulations comprising a pyrethroid and a glycol present in a concentration of from 40.0% by weight to 99.0% by weight based upon the total weight of all components in the composition is disclosed. | 2008-11-06 |
20080275116 | Carboxilic acid derivatives - A compound represented by the following general formula (I) or a salt thereof, or a hydrate thereof or a solvate thereof having an inhibitory action against plasminogen activator inhibitor-1 (PAI-1): | 2008-11-06 |
20080275117 | Compositions and Methods Comprising Boswellia Species - In certain aspects the invention features novel compositions and pharmaceutical preparations of the same. In certain embodiments, the compositions comprise α- and/or β-boswellic acid and/or their C-acetates in an amount greater than 65% by weight. | 2008-11-06 |
20080275118 | HEALTH AND COSMETIC COMPOSITION AND REGIME FOR STIMULATING HAIR GROWTH AND THICKENING ON THE HEAD, INCLUDING THE SCALP, EYELASHES, AND EYEBROWS, AND WHICH DISCOURAGES HAIR LOSS - This invention relates to compositions and processes for stimulating the growth of mammalian hair comprising the topical application of compositions comprising a hair growth stimulating and/or hair loss prevention agent, and a hair and/or skin lightening and/or neutralization agent, in association with a topical pharmaceutical carrier. Unlike other products, the composition of the invention can be used with dyed/treated hair so as to not affect the color of the hair. | 2008-11-06 |
20080275119 | Treatment and Prevention of Liver Disease Associated with Parenteral Nutrition (PN) - The present invention is based on the discovery that parenteral nutrition (PN) induced liver disease, e.g. fatty liver disease, can be prevented and even reversed by administration of primarily omega-3-fatty acid with PN rather than the administration of the standard intravenous lipid emulsions that contain primarily plant derived omega-6 fatty acid. Thus, the present invention provides a method for treating or preventing liver disease in a human patient obtaining nutritional support through PN. The method comprises intravenous administration of an effective amount of an omega-3-fatty acid emulsion to the patient, wherein the patient is not administered phytosterols or plant derived fatty acids, e.g. omega-6 fatty acids derived from a plant source, and wherein the administration of the omega-3-fatty acid emulsion to the patient is for a period greater than three weeks. Preferably, the administration is for a period of greater than six weeks. More preferably, the administration is for a period greater than three months. | 2008-11-06 |
20080275120 | LEUCINE RICH COMPOSITION - The invention relates to the use of a composition comprising proteinaceous matter, said providing at least 24.0% of the energetic value of the composition (en %) and at least 12 wt. % based on proteinaceous matter leucine in the manufacture of a medicament for the treatment of insulin resistance and to a composition suitable for administration to a mammal comprising a protein fraction, a carbohydrate fraction and a lipid fraction, wherein the protein fraction provides at least 24.0 % (en %), the carbohydrate provides up to 46 en %, the lipid fraction provides up to 30 en % and wherein at least 12 wt. %, based on proteinaceous matter, of leucine. | 2008-11-06 |
20080275121 | N-HALOGENATED AMINO ACID FORMULATIONS AND METHODS FOR CLEANING AND DISINFECTION - The present invention relates to methods for disinfecting or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid and a phase transfer agent for a time sufficient to disinfect or clean the lens. This specification further discloses a formulation for disinfecting a contact lens comprising an N-halogenated amino acid and a phase transfer agent. | 2008-11-06 |
20080275122 | N-HALOGENATED AMINO ACID FORMULATIONS WITH ANTI-INFLAMMATORY COMPOUNDS - The present invention relates to a formulation having antimicrobial activity comprising a N-halogenated amino acid and a anti-inflammatory compound. This specification also describes methods for treating a tissue infection comprising contacting the infected tissue with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a anti-inflammatory compound. This specification further describes a method for treating respiratory infections comprising contacting the site of the respiratory infection with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a anti-inflammatory compound. | 2008-11-06 |
20080275123 | N-HALOGENATED AMINO ACID FORMULATIONS - The present invention relates to a method for treating a tissue infection comprising contacting the infected tissue with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a phase transfer agent. This specification also describes a formulation having antimicrobial activity comprising a N-halogenated amino acid and a phase transfer agent. | 2008-11-06 |
20080275124 | POWDER OF AMINO ACIDS AND METHOD FOR PRODUCING THE SAME - Dry powders of amino acids which exhibit great oral meltability and solubility, may be produced by spray drying a hydrous liquid of amino acids to produce a powder of amino acids, where the hydrous liquid of amino acids is prepared into the form of microfine liquid droplets in the presence of trehalose for spray drying, to obtain a powder having a mean particle size of 0.1 μm to 15 μm, as well as granulating and drying during the spray drying or after the spray drying, to obtain a granulated powder having a mean particle size of 20 μm to 1,000 μm. | 2008-11-06 |
20080275125 | Combination Composition - A combination pharmaceutical composition for the treatment of pain including about 125 mg to about 150 mg ibuprofen and about 475 mg to about 500 mg paracetamol. | 2008-11-06 |
20080275126 | ALIPHATIC ACID-CONTAINING N-HALOGENATED AMINO ACID FORMULATIONS - The present invention relates to methods for treating an infected tissue comprising treating the infected tissue with a formulation comprising a N-halogenated amino acid and an aliphatic acid. This specification also discloses methods for improving the antimicrobial activity of a formulation comprising a N-halogenated amino acid, the method comprising adding an aliphatic acid to said formulation. | 2008-11-06 |
20080275127 | Arylsulfonamido-substituted hydroxamic acid derivatives - α-Amino hydroxamic acid derivative of the formula I, | 2008-11-06 |